Although there were a reduction in malaria burden, with 30% fewer cases in 2018 than in 2014, malaria remains a major public health problem in Peru, mainly in the Amazon region where over 44,000 cases were reported in 2018 (96% of cases in the country). Plasmodium vivax is the predominant species, representing 75.5% of malaria cases, similar to the rest of the region of the Americas. P. vivax infections are characterized by frequent relapses due to persistent liver dormant parasites. Previous studies of our research group in the Peruvian Amazon have shown high proportion of recurrence after radical cure (~75% in one year of follow-up [1]). This study aimed to describe the evolution of parasitemia after a supervised radical cure treatment in an endemic rural village in the Peruvian Amazon follow-up by both, molecular tools (qPCR) and thick smear, during one month.

Objetivos. Identificar los factores que afectan o facilitan el uso de los mosquiteros tratados con insecticida de larga duración luego de un año de su distribución en el distrito de San Juan - Loreto. Materiales y métodos. De Octubre a Diciembre del 2010, el Fondo mundial de lucha contra el SIDA, la tuberculosis y la malaria distribuyó 21 174 MTILD Olyset Net® en 67 comunidades del distrito de San juan, que protegieron a 7 558 familias. Entre Enero a Marzo del 2012, luego de seleccionar una muestra de 400 hogares en 20 comunidades se realizaron visitas colectándose mediante un cuestionario semiestructurado información demográfica, de conocimientos, aptitudes y uso de MTILD. Resultados. La posesión de MTILD en hogares luego de un año de su distribución fue elevada (99%). La razón MTILD/persona disminuyó de 0.70 a 0.52, estimándose una retención de 73% MTILD. 74.0% de los n...

Resistance and therapeutic failure to Plasmodium vivax treatment is an increasing problem due to parasite recurrences that sustain transmission. This study aimed to describe clinical and parasitological response after initiation of supervised radical cure treatment in two villages in the Peruvian Amazon follow up by both, molecular tools (qPCR) and thick smear, for 28 days. Thirty-one participants with uncomplicated vivax malaria were recruited from March 2016 to January 2017 in Santa Emilia and San José de Lupuna, river travel is the only way from these endemic rural villages to other places. At the recruitment (day 0), treatment was started with chloroquine 25mg/Kg in 3 days plus primaquine 0.5 mg/Kg/day for 7 days (according to national guidelines in Peru). Clinical and parasitological evaluations were done on days 2, 3, 7, 14, 21 and 28. Although more therapeutic failures were detec...